IRA side effect: Pharma companies will increasingly skip Medicare altogether, Lilly CEO says
As the Centers for Medicare and Medicaid Services races to finalize guidance on how it will negotiate — or dictate, depending on if you ask a pharma exec — the prices of the costliest medicines in the US, pharma execs are warning of unwanted repercussions.
Eli Lilly CEO David Ricks told JP Morgan analysts on Wednesday that for some new drugs, companies might just skip out on seeking entry into the Medicare program altogether.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.